GlassScriptPhysician profile
Philomena Salvemini Hilton
NPI 1992833958
$2,665.49
in general payments reported to CMS, 2019-2025
33 companies · $273 in 2025
The $273 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $323 · 2021: $191 · 2022: $140 · 2023: $960 · 2024: $542 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,775.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $712.33 | 2019-2025 | Qulipta, Lo Loestrin Fe, Ubrelvy |
| Sumitomo Pharma America, INC. | $454.42 | 2023-2024 | Myfembree, Gemtesa |
| Novo Nordisk INC | $216.73 | 2019-2025 | Wegovy |
| Mayne Pharma Commercial LLC | $180.46 | 2023-2025 | |
| Pfizer INC. | $177.71 | 2019-2025 | |
| Hologic Sales and Service, LLC | $134.21 | 2020-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
| Organon LLC | $97.58 | 2023-2025 | Nexplanon |
| Therapeuticsmd, INC. | $68.80 | 2019-2020 | |
| Astellas Pharma US INC | $64.06 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $55.08 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $39.30 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $38.52 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $38.32 | 2019 | |
| Lilly USA, LLC | $33.91 | 2025 | Zepbound |
| Aspira Women'S Health INC | $30.82 | 2023-2024 | Ova1 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $28.66 | 2020 | |
| Daiichi Sankyo INC. | $27.67 | 2020 | |
| Millicent US INC | $27.54 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Medtronic, INC. | $23.80 | 2023 | Ligasure |
| Mycovia Pharmaceuticals, INC. | $22.83 | 2023 | Vivjoa |
| Exact Sciences Corporation | $21.82 | 2024 | Cologuard Collection Kit |
| Vivus LLC | $19.70 | 2025 | Pancreaze |
| Gynesonics, INC. | $18.77 | 2022 | |
| Shield Therapeutics INC | $16.24 | 2024 | |
| Cosette Pharmaceuticals INC. | $15.02 | 2025 | Vyleesi |
| Becton, Dickinson and Company | $14.80 | 2023 | Bd Onclarity |
| Amgen INC. | $14.53 | 2023 | Evenity, Prolia |
| Ethicon US, LLC | $13.26 | 2020 | |
| Allergan, INC. | $12.48 | 2020 | |
| Eisai INC. | $12.06 | 2019 | |
| Agile Therapeutics, INC. | $11.57 | 2021 | |
| Bausch Health US, LLC | $11.32 | 2020 | |
| Roche Diagnostics Corporation | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philomena Hilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.